After carefully reading and trying to understand the research on Molecular Complexity of Colorectal Cancer written by Zhengdong Yang1 and friends in the journal Cancer Management and Research, we conclude that this study has several advantages such as Deep Understanding of Molecular Complexity, Biomarker Identification, Personalized Therapy Approach, Innovation in Early Detection, Development of New Therapy Strategies, and Clinical Relevance. Overall, this study makes a meaningful contribution in understanding colorectal cancer and developing a more effective approach to diagnosis and treatment.

However, there are several shortcomings, such as limitations in biomarker identification where many biomarkers are still not explored in depth, meaning that there is still a lot of potential that has not been utilized in the development of effective biomarkers. In a study conducted by Sophie Paczesny2 about the potential for exploring targeted therapeutics for experimental research. This is also in line with research by Ashish Kumar Gupta3 and friends who used the platform for protein biomarker-based monitoring of pharmacological efficacy in Parkinson’s disease and schizophrenia. In addition, there are limitations in Genetic and Epigenetic Research, which show that their understanding of the molecular complexity of CRCs is far from complete. This is in line research by Alyson Ashe and friends4 who explored the effects of epigenetic inheritance and transgenerational epigenetic inheritance on phenotypic plasticity and adaptation and how these may help drive evolution.

The shortcomings of this study are the limitations of clinical research where the study may not provide enough clinical data supporting the effectiveness of the approach in a broader clinical setting. This is in line clinical research by Jun Liu5 and friends on multidrug-resistant K. pneumoniae infections with more obvious inflammatory responses which calls for more respiratory support and timely clinical management.

Overall, this study provides valuable insights the molecular complexity of CRC, but there are still many challenges that need to be addressed to improve the understanding and effective treatment of this disease.

The author reports no conflicts of interest in this communication.

1. Zhengdong Yang and friends. Molecular Complexity of Colorectal Cancer: Pathways, biomarkers, and therapeutic strategies. Cancer Manage Res. 2024. doi:10.2147/CMAR.S481656

2. Paczesny S. Biomarkers for the detection of graft-versus-host disease in cancer patients after bone marrow transplantation. Current Biomarker Findings. 2012;2012(2):29–42. doi:10.2147/CBF.S27599

3. Ashish Kumar Gupta and friends. 2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia. Neuropsychiatr Dis Treat. 2019. doi:10.2147/NDT.S198559

4. Ashe A, Colot V, Oldroyd BP. How does epigenetics influence the course of evolution? 2021. Philos Trans R Soc B. 2021;376:20200111. doi:10.1098/rstb.2020.0111

5. Liu J, Zhang Y, Cai J. Clinical and microbiological characteristics of Klebsiella pneumoniae Co-Infections in Pulmonary Tuberculosis: A retrospective study. Infect Drug Resist. 2023;Volume 16:7175–7185. doi:10.2147/IDR.S421587